Prostate cancer is the most common type of cancer among men, with approximately 1 in 8 men receiving a diagnosis in their lifetime. Fortunately, prostate cancer is most often slow-growing and highly treatable. The long-term survival rate is high when the cancer is diagnosed early.
At Virginia Oncology Associates (VOA), our oncologists provide patient-centered care and access to the latest prostate cancer treatments, including clinical trials. We have locations throughout Virginia and Eastern North Carolina, including Chesapeake, Elizabeth City, Hampton, Newport News, Norfolk, Suffolk, Virginia Beach, and Williamsburg.
Explore the following sections to learn more about how prostate cancer is detected and treated so you can make informed decisions about your care.
If you were recently diagnosed with prostate cancer, we encourage you to meet with an oncologist to discuss your treatment options. The cancer care team at VOA is here to guide newly diagnosed prostate cancer patients through their cancer journey. From starting with a comprehensive consultation to creating a treatment plan and explaining what to expect after prostate cancer treatment, we are here to guide you every step of the way.
The stage of prostate cancer will influence when you need treatment and which treatment options will be most effective. The prostate cancer doctor will assess the location and size of the tumor, along with the Gleason Score and PSA test results, to determine the stage of cancer. Your risk group will also be determined, indicating the likelihood of localized cancer spreading outside the prostate.
Prostate cancer does not always require surgery or an immediate treatment plan. Your prostate cancer specialist at Virginia Oncology Associates will review your test results and talk about whether you can use an active surveillance approach or if they feel it is time to start treatment. Based on your cancer stage and overall health, we will work together to develop a prostate cancer treatment plan that’s best for you.
At Virginia Oncology Associates, we are fortunate to collaborate with the Duke University Oncology Consortium, the National Cancer Institute, the US Oncology Network, the Sarah Cannon Research Institute (SCRI), and other major cancer centers. VOA has over 70 ongoing clinical trials for cancer, giving patients access to new therapies. Through these partnerships, we provide our community in Hampton Roads, Eastern North Carolina, and the surrounding areas with the most advanced treatment technologies. Find out if a prostate cancer clinical trial might be suitable for you.
For newly diagnosed patients with prostate cancer, it’s important to understand all your options and focus on the best treatment plan for you. Learn more about the commonly asked questions and answers about prostate cancer.
Virginia Oncology Associates provides support for prostate cancer patients and their loved ones during and after treatment. We offer support groups, community resources, genetic testing and counseling, financial counseling through our Patient Benefit Representatives, and many other programs. We encourage you to learn more and take advantage of our supportive care services.
The Prostate Cancer Foundation is a prostate cancer-specific organization that you might find helpful.
If you or a loved one has been recently diagnosed with prostate cancer, the oncologists at Virginia Oncology Associates are here to help you through your journey. We offer comprehensive, compassionate care and the latest prostate cancer treatments tailored to you. Our cancer centers are located throughout cities in Hampton Roads and Eastern North Carolina, including Virginia Beach, Norfolk, Hampton, Williamsburg, Chesapeake, Suffolk (Obici and Harbour View), Newport News, and Elizabeth City.
Early detection and self-advocacy are the keys to combating prostate cancer. In this episode of Cancer Care Connections, Dr. Mark Fleming, medical oncologist at Virginia Oncology Associates, shares his insights and experience with prostate cancer. He also discusses the importance of the PSA test, which plays a critical role in the early diagnosis of prostate cancer.
